Comparison of human chordoma cell-kill for 290 MeV/n carbon ions versus 70 MeV protons in vitro

Radiation Oncology

Takamitsu A Kato³  Mitsuru Uesaka⁴  Akira Fujimori¹  Hisashi Kitamura²  Paula C Genik³  Hiroshi Fujisawa⁴ 

[1] Research Center for Charged Particle Therapy, Molecular Target Research Unit, International Open Laboratory, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage, Chiba, 263-8555, Japan;Research Development and Support Center, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage, Chiba, 263-8555, Japan;Department of Environmental & Radiological Health Sciences, Colorado State University, 1618 Campus Delivery, Fort Collins, CO, 80523, USA;Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo, 113-8656, Japan

关键词: Bragg peak;    Proton;    Carbon;    High LET;    OptiCell™;    Chordoma;    Particle radiotherapy;   

Others  :  1154171
DOI  :  10.1186/1748-717X-8-91

 received in 2013-01-21, accepted in 2013-04-11,  发布年份 2013

【 摘 要 】

Background

While the pace of commissioning of new charged particle radiation therapy facilities is accelerating worldwide, biological data pertaining to chordomas, theoretically and clinically optimally suited targets for particle radiotherapy, are still lacking. In spite of the numerous clinical reports of successful treatment of these malignancies with this modality, the characterization of this malignancy remains hampered by its characteristic slow cell growth, particularly in vitro.

Methods

Cellular lethality of U-CH1-N cells in response to different qualities of radiation was compared with immediate plating after radiation or as previously reported using the multilayered OptiCell™ system. The OptiCell™ system was used to evaluate cellular lethality over a broad dose-depth deposition range of particle radiation to anatomically mimic the clinical setting. Cells were irradiated with either 290 MeV/n accelerated carbon ions or 70 MeV accelerated protons and photons and evaluated through colony formation assays at a single position or at each depth, depending on the system.

Results

There was a cell killing of approximately 20–40% for all radiation qualities in the OptiCell™ system in which chordoma cells are herein described as more radiation sensitive than regular colony formation assay. The relative biological effectiveness values were, however, similar in both in vitro systems for any given radiation quality. Relative biological effectiveness values of proton was 0.89, of 13–20 keV/μm carbon ions was 0.85, of 20–30 keV/μm carbon ions was 1.27, and >30 keV/μm carbon ions was 1.69. Carbon-ions killed cells depending on both the dose and the LET, while protons depended on the dose alone in the condition of our study. This is the first report and characterization of a direct comparison between the effects of charged particle carbon ions versus protons for a chordoma cell line in vitro. Our results support a potentially superior therapeutic value of carbon particle irradiation in chordoma patients.

Conclusion

Carbon ion therapy may have an advantage for chordoma radiotherapy because of higher cell-killing effect with high LET doses from biological observation in this study.

【 授权许可】

   
2013 Fujisawa et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Bhide SA, Nutting CM: Recent advances in radiotherapy. BMC Med 2010, 8:25. BioMed Central Full Text
• [2]Durante M, Loeffler JS: Charged particles in radiation oncology. Nat Rev Clin Oncol 2010, 7(1):37-43.
• [3]Tobias CA, Lyman JT, Chatterjee A, Howard J, Maccabee HD, Raju MR, Smith AR, Sperinde JM, Welch GP: Radiological physics characteristics of the extracted heavy ion beams of the bevatron. Science 1971, 174(4014):1131-1134.
• [4]Imai R, Kamada T, Sugahara S, Tsuji H, Tsujii H: Carbon ion radiotherapy for sacral chordoma. Br J Radiol 2011, 84 Spec No 1:S48-S54.
• [5]Jingu K, Tsujii H, Mizoe JE, Hasegawa A, Bessho H, Takagi R, Morikawa T, Tonogi M, Tsuji H, Kamada T: Carbon ion radiation therapy improves the prognosis of unresectable adult bone and soft-tissue sarcoma of the head and neck. Int J Radiat Oncol Biol Phys 2012, 82(5):2125-2131.
• [6]Imai R, Kamada T, Tsuji H, Sugawara S, Serizawa I, Tsujii H, Tatezaki S: Effect of carbon ion radiotherapy for sacral chordoma: results of phase I-II and phase II clinical trials. Int J Radiat Oncol Biol Phys 2010, 77(5):1470-1476.
• [7]Kamada T: Efficacy and safety of carbon Ion radiotherapy in bone and soft tissue sarcomas. J Clin Oncol 2002, 20(22):4466-4471.
• [8]Schulz-Ertner D, Nikoghosyan A, Thilmann C, Haberer T, Jakel O, Karger C, Scholz M, Kraft G, Wannenmacher M, Debus J: Carbon ion radiotherapy for chordomas and low-grade chondrosarcomas of the skull base. Results in 67 patients. Strahlenther Onkol 2003, 179(9):598-605.
• [9]Schulz-Ertner D, Haberer T, Jakel O, Thilmann C, Kramer M, Enghardt W, Kraft G, Wannenmacher M, Debus J: Radiotherapy for chordomas and low-grade chondrosarcomas of the skull base with carbon ions. Int J Radiat Oncol Biol Phys 2002, 53(1):36-42.
• [10]Casali PG, Stacchiotti S, Sangalli C, Olmi P, Gronchi A: Chordoma. Curr Opin Oncol 2007, 19(4):367-370.
• [11]Mendenhall WM, Mendenhall CM, Lewis SB, Villaret DB, Mendenhall NP: Skull base chordoma. Head Neck 2005, 27(2):159-165.
• [12]Sundaresan N: Chordomas. Clin Orthop Relat Res 1986, 204:135-142.
• [13]Henderson FC, McCool K, Seigle J, Jean W, Harter W, Gagnon GJ: Treatment of chordomas with CyberKnife: georgetown university experience and treatment recommendations. Neurosurgery 2009, 64(2 Suppl):A44-A53.
• [14]Schulz-Ertner D, Nikoghosyan A, Didinger B, Karger CP, Jakel O, Wannenmacher M, Debus J: Treatment planning intercomparison for spinal chordomas using intensity-modulated photon radiation therapy (IMRT) and carbon ions. Phys Med Biol 2003, 48(16):2617-2631.
• [15]Combs SE, Ellerbrock M, Haberer T, Habermehl D, Hoess A, Jakel O, Jensen A, Klemm S, Munter M, Naumann J: Heidelberg Ion therapy center (HIT): initial clinical experience in the first 80 patients. Acta Oncol 2010, 49(7):1132-1140.
• [16]Kato TA, Tsuda A, Uesaka M, Fujimori A, Kamada T, Tsujii H, Okayasu R: In vitro characterization of cells derived from chordoma cell line U-CH1 following treatment with X-rays, heavy ions and chemotherapeutic drugs. Radiat Oncol 2011, 6:116. BioMed Central Full Text
• [17]Scheil S, Bruderlein S, Liehr T, Starke H, Herms J, Schulte M, Moller P: Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer 2001, 32(3):203-211.
• [18]Kuzniacka A, Mertens F, Strombeck B, Wiegant J, Mandahl N: Combined binary ratio labeling fluorescence in situ hybridization analysis of chordoma. Cancer Genet Cytogenet 2004, 151(2):178-181.
• [19]Hallor KH, Staaf J, Jonsson G, Heidenblad M, von SF V, Bauer HC, Ijszenga M, Hogendoorn PC, Mandahl N, Szuhai K, Mertens F: Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisation. Br J Cancer 2008, 98:434-442.
• [20]Duong HS, Le AD, Zhang Q, Messadi DV: A novel 3-dimensional culture system as an in vitro model for studying oral cancer cell invasion. Int J Exp Pathol 2005, 86(6):365-374.
• [21]Genet SC, Maeda J, Fujisawa H, Yurkon CR, Fujii Y, Romero AM, Genik PC, Fujimori A, Kitamura H, Kato TA: Comparison of cellular lethality in DNA repair-proficient or -deficient cell lines resulting from exposure to 70 MeV/n protons or 290 MeV/n carbon ions. Oncol Rep 2012, 28((5)):1591-1596.
• [22]Kanai T, Endo M, Minohara S, Miyahara N, Koyama-ito H, Tomura H, Matsufuji N, Futami Y, Fukumura A, Hiraoka T: Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy. Int J Radiat Oncol Biol Phys 1999, 44(1):201-210.
• [23]Hiraoka T, Hoshino K, Fukumura A, Kawashima K: Dosimetry of 70 MeV proton beams from the NIRS cyclotron. Medical dosimetry : official journal of the American Association of Medical Dosimetrists 1990, 15(2):79-81.
• [24]Akanuma A, Majima H, Furukawa S, Okamoto R, Nakamura YK, Tsunemoto H, Morita S, Arai T, Kurisu A, Hiraoka T: Compensation techniques in NIRS proton beam radiotherapy. Int J Radiat Oncol Biol Phys 1982, 8(9):1629-1635.
• [25]Raju MR, Bain E, Carpenter SG, Cox RA, Robertson JB: A heavy particle comparative study. Part II: cell survival versus depth. Br J Radiol 1978, 51(609):704-711.
• [26]Matsufuji N, Kanai T, Kanematsu N, Miyamoto T, Baba M, Kamada T, Kato H, Yamada S, Mizoe JE, Tsujii H: Specification of carbon Ion dose at the national institute of radiological sciences (NIRS. JRadiatRes(Tokyo) 2007, 48 Suppl A:A81-A86.
• [27]Kagawa K, Murakami M, Hishikawa Y, Abe M, Akagi T, Yanou T, Kagiya G, Furusawa Y, Ando K, Nojima K: Preclinical biological assessment of proton and carbon ion beams at hyogo Ion beam medical center. Int J Radiat Oncol Biol Phys 2002, 54(3):928-938.
• [28]Smith R, Smith KA, Biggs CA, Scheck AC: In vitro biological dosimeter modeling of the glioblastoma response to radiation delivered by the gamma knife. Laboratory investigation. J Neurosurg 2010, 113(Suppl):222-227.
• [29]Courdi A, Brassart N, Herault J, Chauvel P: The depth-dependent radiation response of human melanoma cells exposed to 65 MeV protons. Br J Radiol 1994, 67(800):800-804.
• [30]Ando K, Furusawa Y, Suzuki M, Nojima K, Majima H, Koike S, Aoki M, Shimizu W, Futami Y, Ogino T: Relative biological effectiveness of the 235 MeV proton beams at the national cancer center hospital east. J Radiat Res 2001, 42(1):79-89.
• [31]Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C: Clonogenic assay of cells in vitro. Nat Protoc 2006, 1(5):2315-2319.
• [32]Buch K, Peters T, Nawroth T, Sanger M, Schmidberger H, Langguth P: Determination of cell survival after irradiation via clonogenic assay versus multiple MTT assay–a comparative study. Radiat Oncol 2012, 7:1. BioMed Central Full Text
• [33]Franken NAP, VanBree C, Kipp JBA, Barendsen GW: Modification of potentially lethal damage in irradiated chinese hamster V79 cells after incorporation of halogenated pyrimidines. Int J Radiat Biol 1997, 72(1):101-109.